EVALUATION OF ANTI-PARKINSON ACTIVITY OF LEMON GRASS Miss.Rupali Dilip Handal T. Y B. Pharmacy GUIDED BY Prof- Hemant. J. Pagar (M. Pharm. Pharmacology)

Slides:



Advertisements
Similar presentations
Use of Animals in Research into Schizophrenia. Why use animals? Basically, in order to do research you wouldnt be able to do with humans for ethical reasons.
Advertisements

conventional antipsychotic drug
Dopamine Theory of Schizophrenia
Parkinson's Disease Animal Models and Possible Treatments.
The PARticulars of Parkinson’s Disease
DBS on Parkinson’s Disease By: Christopher Ross DeSanto BME 181 / February 11, 2010.
ANTI DIABETIC AND ANALGESIC ACTIVITY OF WITHANIA SOMNIFERA BY SHEENAL DAVDRA U29/35699/2010 SUPERVISOR: DR. S. N. NDWIGAH SCHOOL OF PHARMACY.
Is it a neurodegenerative brain disorder that progresses slowly in most people.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Deep Brain Stimulation For parkinson’s disease
Drugs of Anti-Parkinson’s disease Department of Pharmacology Zhang Yan-mei.
© 2012 The McGraw-Hill Companies, Inc. All rights reserved. 1 Pharmacology: An Introduction CHAPTER.
Antipsychotic drugs. Anti-psychotic drugs The CNS functionally is the most complex part of the body, and understanding drug effects is difficult Understanding.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Chapter 31 Anti-Parkinson Agents. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Parkinson’s.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Motor Response Complications and Cycline-Dependent Kinase 5 (Cdk5) Neuroadaptations in an Animal Model of Parkinson’s Disease Heather Minkel Dr. Justin.
BY: MACKENZIE SOARES ALYSSA MEDIEROS STEPHANIE GARDNER Parkinson's Disease.
Neurotransmitters, Parkinson’s disease and depression
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 16Psychopharmacology.
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Clinical Toxicology & Pharmacology, Newcastle Mater Misericordiae Hospital Neuroleptic Malignant Syndrome Recognition, Risk factors and Management.
Mostly Parkinson’s disease but also few other movement disorders due to diseases of the basal ganglia.
Erin Kibbey, RN, BS, CCRN Psychopharmacology. ›From a historical perspective, reflect on how psychopharmacology has changed mental health nursing ›Explore.
Parkinson’s Disease Dr. Andrew Schmelz, PharmD Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University March 4, 2009.
Quantitative Detection of Parkinson's Disease Symptoms Advisor: Dr. Chris Kao Project Team: Kylen Bares Eddie Cao.
 Parkinson’s Disease (PD) -progressive neurodegenerative disease affecting motor ability -third most common neurologic disorder of older adults.
The evolution of non-motor symptoms in patients with Parkinson’s disease treated with Duodopa intestinal gel Natalia Pritcan Doctor Jozsef Attila Szasz.
How are medicines developed?. What is it? What’s inside?
HOLLY CAMPBELL-BARR, LAUREN GAY AND LUCY GODDEN. The effect of drugs on the brain…
Biological Explanations for Schizophrenia
By: Alejandro Navarro and Andrea Ors. Content Introduction What is Parkinson's disease? What causes the disease? History Main symptoms Treatment Statistics.
By Katelyn Chaimson and Sean Guyot
Α-synuclein transgenic mouse models of Parkinson’s disease Michelle Maurer December 2015.
 Parkinson Disease (PD) is a progressive disorder of the central nervous system that often impairs the sufferer's motor skills, speech, and other functions.
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
By Seamus Hogan.  Parkinsons disease is degenerative disorder of the central nervous system. it causes the dopamine to contain cells in the substantial.
Management of Parkinson’s disease (in the acute medical ward) C. M. James MD FRCP FAcadMEd Consultant Physician Withybush Hospital, Pembrokeshire.
1 RESEARCH AND DEVELOPMENT OF WEIGHT LOSS PRODUCT WITH LIPASE INHIBITORY ACTIVITY SIRINAN TUUBTHIMTHED Department of Pharmaceutical and Natural Products.
ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.
Orange oil, Lemon grass oil, Sandal wood PERFUMES AND FLAVOURS PH
항 파킨슨씨 약물 Anti-Parkinson Drug.
PARKINSON’S DISEASE CHAMINDA UNANTENNE RN,MS,MSN.
“HEALTH IS THE BEST” In the name of God. WHAT IS IT? Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Drugs Used for Parkinson’s Disease
Sindhu G. & Dr. A. Helen Department of Biochemistry
Modelling Madness Susan Totterdell.
Preliminary Phytochemical Investigation of Antidesma acidum Retz
Parkinson's disease KRZYSZTOF NICPOŃ.
Use of Animals in Research into Schizophrenia
The Effect of Caffeine and Ephedrine Combination on Weight Loss and Lipid Profile of Newzealand Rabbits.
Dopamine AND PD.
Prediction of Parkinson’s Disease Tremor Onset Using Artificial Neural Networks Kevin Warwick.
Treatment of Parkinson’s disease
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson’s disease.
Parkinson's disease Parkinson's disease (PD) is the second-most common
Justin Hayase MSTAR Presentation Guo Lab July 23,2009
ANTIPARKINSONS Drugs By Dr. Mirza Shahed Baig.
Pharmacology of Ayahuasca
Antipsychotic Agents and Their Use in Schizophrenia
Periulcerous inflammation
Drug-induced dyskinesias
Athetosis, dystonia, tics
Parkinsonism and Anesthesia
Drug induced parkinsonism
Sertraline In this section we’ll discuss the most relevant aspects of sertraline.
Justin Hayase MSTAR Presentation Guo Lab July 23,2009
Drugs for Degenerative Diseases of the Nervous System
Presentation transcript:

EVALUATION OF ANTI-PARKINSON ACTIVITY OF LEMON GRASS Miss.Rupali Dilip Handal T. Y B. Pharmacy GUIDED BY Prof- Hemant. J. Pagar (M. Pharm. Pharmacology)

CONTENT Introduction Objectives Review of literature Methodology Experimentation Result Conclusion References

INTRODUCTION Parkinsons disease is a Neurodegenerative disorder of central nervous system.It was first described in 1817 by James Parkinson. This disease is occure due to low level of dopamine. SYMPTOMS OF DISEASE  Tremor  Rigidity  Bradykinesia  Depression

OBJECTIVES To study the Anti-Parkinson Activity of cymbopogon citratus (lemon grass). The lemon grass plant having the anti- parkinson activity, The present study is planed with the following objectives To prepare the ethanolic extract of lemon grass. To evaluate the traditional claim of its anti-parkinson activity. To determime probable action of the extract under study of its anti-parkinsons activity.

REVIEW OF LITERATURE Name of plant- cymbopogon citrates Synonym- lemon grass, gavati chaha Family- poaceae

METHODOLOGY  Plant material  Animals  Determination of acute toxicity study (LD 50 ) IN-VIVO STUDIES  Haloperidol-Induced catalepsy in rats Neuroleptic agent also induced catalepsy, but with different mechanism. Neuroleptics inhibit dopamine D 2 receptar in the substantia nigra. Since the catalepsy is a common extrapyramidal side effect of neuroleptic agents. This experiment carried out by using block method.

EXPERIMENTATION Sr noAnimal for testingDrugBody wtDose 1NormalDistilled water ml 2Negative controlHaloperidol ml 3Positive control LDopa+ haloperidol mg+0.16 ml 4Test 1 Test drug + haloperidol mg+0.2ml 5Test 2 Test drug + haloperidol mg Test 3Test drug + haloperidol mg+0.18ml

Normal00 0 ± 0 Negative control (Haloperidol) ## ± 0.48 Positive control (levodopa carbidopa + haloperidol) ** ± 0.18 Test 1 C.C Extract 200mg ± 0.48 Test C.C Extract 400mg** ± 0.31 Test C.C Extract 800mg** ± 0.25 Treatment (Dose in mg/kg) Duration of Catelepsy in min at Effect of ethanolic extract of lemon grass RESULT

Fig- Animal showing 3 rd stage of catatonia

Fig-Animal showing 4 th stage of catatonia

CONCLUSION The chymbopogon citratus extract 400 mg and 800 mg shows significant effect when compared with that of standard. So, the test extract exibit anti-parkinson activity, which may be due to the phytochemical constituents present in the extract of chymbopogon citratus. The lemon grass contains a chemical constituent i.e. Citral which has a close structural similarity with that of dopamine. So, our activity may be due to this structural similarity to dopamime. Hence, further studies need to be carried out in this regard to verify the activity of lemon grass.

REFERENCES  Kokate CK, Purohit AP, Gokhle SB. Pharmacognosy,13 th edition. Nirali Prakashan: pune,India, 1994  Kulkarni SK. Handbook of Experimental Pharmacology,3 rd edition. Vallabh Prakashan: Delhi, India,2004  Essentials of Medical Pharmacology six edition.KD tripathi page no  Rang and Dales Pharmacology Seventh edition page no ,463.  Lippincott’s illustrated reviews Pharmacology 4 th edition page no